Polycomb repressors and epigenetic therapy

DNA repair and mutations as targets for personalised therapy

The changing process of drug discovery and design

Glioblastoma heterogeneity in circulating tumour DNA

ERß expression predicts breast cancer risk in hyperplasia

Advances in early detection

Polygenic risk and the targeted prevention of cancer

Mouse models of lung cancer

Deciphering RAS/MAPK signalling in cancer

Changing landscape of multiple myeloma care: Expert discussion

Monitoring the cancer genome in plasma using circulating tumour DNA

Models and critical preclinical data shaping personal therapy